FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4240474188> ?p ?o ?g. }

• W4240474188 endingPage "178" @default.
• W4240474188 startingPage "178" @default.
• W4240474188 abstract "Sir, We thank Mundra for a detailed analysis of our paper, and for his attempt to improve the impact of our findings.[1] In our study, 152 subjects were on plain Vildagliptin while 148 were on a fixed dose combination of vildagliptin and metformin. The uptitration of the dose was based on the glycemic control achieved. There was no protocol followed for the uptitration of the dosages A significant drop was reported in both the groups (on vildagliptin as well as vildagliptin and metformin combination). The baseline fasting plasma glucose in plain and combination groups was 195.61 ± 57.91 and 194.26 ± 54.56 mg% respectively, which came down to 121.84 ± 27.52 and 128.11 ± 32.33 mg% respectively. Also, the baseline postprandial glucose in plain and combination of 287.43 ± 85.62 and 287.77 ± 69.94 mg% came down to 165.60 ± 34.00 and 178.67 ± 39.65 mg% respectively. The HbA1c changes were significant: Values of 9.04 ± 1.45 and 8.99 ± 1.12% came down to levels of 7.61 ± 1.04 and 7.69 ± 0.99% respectively. Dipeptidyl peptidase (DPP)-4 inhibitors are generally weight-neutral, although modest weight loss has been observed with the DPP-4 inhibitor, vildagliptin, in patients with relatively low baseline glycemia. The weight neutrality of vildagliptin likely results in part from its intrinsically low risk for hypoglycemia. Recent studies point to additional potential mechanisms. One study found that drug-naοve patients randomized to vildagliptin exhibited significantly lower chylomicron lipid and apolipoprotein levels than placebo patients, suggesting that vildagliptin may inhibit intestinal fat extraction. Another trial found that patients randomized to vildagliptin versus placebo experienced paradoxical postprandial increases in markers of fatty acid mobilization and oxidation, in conjunction with increased sympathetic stimulation. Elaboration of these and other pathways could further clarify the origins of the favorable weight profile of vildagriptin.[2] Adverse event reporting was only kept for hypoglycaemia, which was not observed during the trial period in any of the group. We agree with Dr. Mundra that we definitely need more randomized trials to further elucidate the role of DPP-IV inhibitors and their benefit in terms of cardiac, lipids and insulin sensitivity.[1]" @default.
• W4240474188 created "2022-05-12" @default.
• W4240474188 creator A5031524243 @default.
• W4240474188 creator A5050130423 @default.
• W4240474188 date "2013-01-01" @default.
• W4240474188 modified "2023-10-18" @default.
• W4240474188 title "Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus" @default.
• W4240474188 doi "https://doi.org/10.4103/2230-8210.107877" @default.
• W4240474188 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23776879" @default.
• W4240474188 hasPublicationYear "2013" @default.
• W4240474188 type Work @default.
• W4240474188 citedByCount "0" @default.
• W4240474188 crossrefType "journal-article" @default.
• W4240474188 hasAuthorship W4240474188A5031524243 @default.
• W4240474188 hasAuthorship W4240474188A5050130423 @default.
• W4240474188 hasBestOaLocation W42404741881 @default.
• W4240474188 hasConcept C126322002 @default.
• W4240474188 hasConcept C134018914 @default.
• W4240474188 hasConcept C162156334 @default.
• W4240474188 hasConcept C2776453732 @default.
• W4240474188 hasConcept C2777180221 @default.
• W4240474188 hasConcept C2778199505 @default.
• W4240474188 hasConcept C2780323712 @default.
• W4240474188 hasConcept C2780473172 @default.
• W4240474188 hasConcept C2780668416 @default.
• W4240474188 hasConcept C555293320 @default.
• W4240474188 hasConcept C71924100 @default.
• W4240474188 hasConcept C98274493 @default.
• W4240474188 hasConceptScore W4240474188C126322002 @default.
• W4240474188 hasConceptScore W4240474188C134018914 @default.
• W4240474188 hasConceptScore W4240474188C162156334 @default.
• W4240474188 hasConceptScore W4240474188C2776453732 @default.
• W4240474188 hasConceptScore W4240474188C2777180221 @default.
• W4240474188 hasConceptScore W4240474188C2778199505 @default.
• W4240474188 hasConceptScore W4240474188C2780323712 @default.
• W4240474188 hasConceptScore W4240474188C2780473172 @default.
• W4240474188 hasConceptScore W4240474188C2780668416 @default.
• W4240474188 hasConceptScore W4240474188C555293320 @default.
• W4240474188 hasConceptScore W4240474188C71924100 @default.
• W4240474188 hasConceptScore W4240474188C98274493 @default.
• W4240474188 hasIssue "1" @default.
• W4240474188 hasLocation W42404741881 @default.
• W4240474188 hasLocation W42404741882 @default.
• W4240474188 hasLocation W42404741883 @default.
• W4240474188 hasLocation W42404741884 @default.
• W4240474188 hasOpenAccess W4240474188 @default.
• W4240474188 hasPrimaryLocation W42404741881 @default.
• W4240474188 hasRelatedWork W1591133904 @default.
• W4240474188 hasRelatedWork W2045289623 @default.
• W4240474188 hasRelatedWork W2102382908 @default.
• W4240474188 hasRelatedWork W2109649769 @default.
• W4240474188 hasRelatedWork W2113449571 @default.
• W4240474188 hasRelatedWork W2158105924 @default.
• W4240474188 hasRelatedWork W2160848318 @default.
• W4240474188 hasRelatedWork W4220781513 @default.
• W4240474188 hasRelatedWork W4233849132 @default.
• W4240474188 hasRelatedWork W4239196869 @default.
• W4240474188 hasVolume "17" @default.
• W4240474188 isParatext "false" @default.
• W4240474188 isRetracted "false" @default.
• W4240474188 workType "article" @default.